🏛️ Verified NIH Record • Updated 2026-05-22
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) (NCT04070209)
The Role of Therapeutic Layering of Stereotactic Body Radiotherapy on Darolutamide in the Management of Oligoprogressive Castration Resistant Prostate Cancer: A Pilot Phase II Trial
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
🩺 Plain-English Summary (8th-Grade Level)
This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.
Who can join: Review the eligibility criteria below.
Location: Prostate Cancer Centre — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Prostate Cancer Centre — Calgary, Alberta
- Centre of Applied Urology Research — Halifax, Nova Scotia
- St. Joseph's Healthcare Hamilton — Hamilton, Ontario
- Hôpital de Gatineau — Gatineau, Quebec
- Service d'urologie et Centre de la prostate — Longueuil, Quebec
- Hôpital Maisonneuve-Rosemont — Montreal, Quebec
- Centre hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec
- Sir Mortimer JGH — Montreal, Quebec
- L'Hôtel-Dieu de Québec (CHUQ) — Québec, Quebec
- Hôpital Fleurimont (CHUS) — Sherbrooke, Quebec
- Centre hospitalier affilié universitaire régional (CHAUR) — Trois-Rivières, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC — Tucson, Arizona
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.